http://ir.achillion.com/releases.cfm?sh_auth=0.0.0.ad1dcb691ef81696c0c02ea27e385165Achillion Pharmaceuticals - General Releasesen-usShareholder.com RSS Feedhttp://ir.achillion.com/releasedetail.cfm?ReleaseID=770773Wed, 12 Jun 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=770773Achillion to Present at the Wells Fargo 2013 Healthcare Conferencehttp://ir.achillion.com/releasedetail.cfm?ReleaseID=768019Thu, 30 May 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=768019Achillion Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCVhttp://ir.achillion.com/releasedetail.cfm?ReleaseID=767648Tue, 28 May 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=767648Achillion Names Milind Deshpande, Ph.D., as President, Chief Executive Officer, Following Announced Retirement of Michael Kishbauchhttp://ir.achillion.com/releasedetail.cfm?ReleaseID=764844Wed, 15 May 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=764844Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Teamhttp://ir.achillion.com/releasedetail.cfm?ReleaseID=763377Thu, 09 May 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=763377Achillion to Present at Three Upcoming Investor Conferenceshttp://ir.achillion.com/releasedetail.cfm?ReleaseID=758324Tue, 23 Apr 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=758324Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congresshttp://ir.achillion.com/releasedetail.cfm?ReleaseID=758318Tue, 23 Apr 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=758318Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patientshttp://ir.achillion.com/releasedetail.cfm?ReleaseID=756688Tue, 16 Apr 2013 13:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=756688Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCVhttp://ir.achillion.com/releasedetail.cfm?ReleaseID=744397Fri, 01 Mar 2013 14:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=744397Achillion to Present at Two Upcoming Investor Conferenceshttp://ir.achillion.com/releasedetail.cfm?ReleaseID=741919Wed, 20 Feb 2013 14:30:00 GMThttp://ir.achillion.com/releasedetail.cfm?ReleaseID=741919Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock